A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Subcutaneously Administered BW-00112 in Patients with Mixed Dyslipidemia
Latest Information Update: 25 Dec 2024
At a glance
- Drugs BW 00112 (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Argo Biopharma
- 19 Dec 2024 Status changed from not yet recruiting to recruiting.
- 19 Jul 2024 New trial record